T he immune system can identify and control nascent tumor cells through a process named cancer immunosurveillance. 1 This process has been the subject of studies in both animal models and cancer patients. However, cancer immunotherapy has so far only shown modest clinical benefits for patients with cancer. This is due to the fact that the immune system can promote tumor progression through chronic inflammation, immunoselection of poorly immunogenic variants, and by suppressing antitumor immunity.
1,2 B7 homolog 1 (B7-H1), also known as programmed death ligand-1 (PDL-1) or CD274, is an inhibitory molecule of T cells that has been implicated in the protection of tumor cells from immune attack.
3 B7-H1 expression, and its association with clinicopathological, prognostic and immunological factors, has been reported in several human malignancies including breast, [4] [5] [6] [7] [8] [9] ovarian, [8] [9] [10] [11] cervical, 12 oral, [13] [14] [15] head and neck, 16, 17 brain, [18] [19] [20] [21] [22] lung, 8, 9, [23] [24] [25] nasopharyngeal, 26, 27 esophageal, 28, 29 gastric, 30 liver, [31] [32] [33] [34] [35] [36] colorectal, 8, 9, 37, 38 pancreatic, [39] [40] [41] [42] [43] [44] renal, [45] [46] [47] [48] [49] [50] urothelial, [51] [52] [53] skin, 9,54-57 and blood cancers. 8, [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] Overexpression of this molecule has been linked to worse prognosis and resistance to anti-cancer therapies in many of these malignancies (Table S1 ). The B7-H1 molecule binds to its receptor, programmed death 1 (PD-1) on tumor specific T cells, which leads to their apoptosis, and thus shields the tumor cells from lysis by activated T cells. 71 Cancer cells also release immunosuppressive cytokines such as transforming growth factor beta (TGF-b), Interferon gamma (IFN-c), and Fas ligand that upregulate B7-H1 expression and further aid the tumor cells to elude immune responses. 72 Further, blocking of B7-H1 or its receptor PD-1 with monoclonal antibodies has been demonstrated to trigger anti-tumor immune responses, and enhance the effectiveness of anti-cancer immunotherapy. 73 Targeting this molecule can therefore lead to a major breakthrough in cancer treatment. This review illustrates the expression and pathological correlations of the B7-H1 molecule in human cancers, its role in carcinogenesis, and its possible therapeutic targeting strategies to enhance the anti-tumor immune response in malignancies.
EXPRESSION OF B7-H1 IN HUMAN CANCERS

B7-H1 expression in solid tumors
Lung cancer The B7-H1 expression was first demonstrated by Konishi et al. 24 in 2004 in frozen tissue specimens of 52 (100%) patients with non small cell lung carcinomas (NSCLC). Both adenocarcinomas and squamous cell carcinomas expressed this molecule. The expression was observed both in the membrane and the cytoplasm of tumor cells in a scattered fashion. However, its expression was not associated with the clinicopathological factors or the survival of the patients. The density of tumor-infiltrating lymphocytes (TILs) was inversely correlated to the B7-H1 positive tumor sites in five patients. Later, Mu et al. (2011) 25 reported the expression of B7-H1 in 58 of 109 (53%) paraffin-embedded specimens of NSCLC patients. B7-H1 positive cells were significantly abundant in adenocarcinomas than in squamous cell carcinomas of the lung. The expression was correlated with survival of less than three years after lobectomy. 25 Very recently, Boland et al. 23 demonstrated expression in 42 of 214 (20%) paraffin-embedded specimens of squamous NSCLC patients. B7-H1 in the tumors was predominantly expressed in the cell membrane and minimally in the cytoplasm. The expression, however, was not significantly correlated with the clinical outcomes. 23 Further studies, preferably on frozen specimens are required to confirm the lower expression of B7-H1 in squamous NSCLC.
Gastric carcinoma B7-H1 expression in gastric carcinoma patients was reported by Wu et al. (2006) . 30 The expression was detected in paraffin-embedded sections of 43 of 102 (42%) gastric carcinoma patients. The expression was significantly associated with tumor size, tumor depth invasion, lymph node metastasis, and reduced survival. B7-H1 was shown to be a significant prognostic factor 30 in gastric carcinoma patients.
Hepatocellular carcinoma (HCC)
In 2009, Gao et al. 32 studied B7-H1 expression in paraffin-embedded specimens of 204 hepatocellular carcinoma (HCC) subjects. Intratumoral B7-H1 expression was an independent prognostic factor for disease free survival. Relapse risk was two times more likely for B7-H1 positive patients after resection surgery compared with B7-H1 negative subjects. B7-H1 positive patients had significantly poor disease free survival and overall survival than B7-H1 negative patients. B7-H1 positive subjects had more tumors with vascular invasion. The expression was positively correlated with Forkhead box P3 (Foxp3) positive regulatory TILs (Tregs). 32 an immunoregulatory T cell population known to downregulate the immune response in cancer.
In parallel with the Gao et al. study, Wu et al. 35 reported elevated B7-H1 expression in 35 of 71 (49%) HCC cases. Patients with elevated B7-H1 expression had significantly poor survival compared with low expression subjects. 35 In 2011, Geng et al. 33 studied B7-H1 expression in 60 HCC cases. Elevated B7-H1 mRNA and protein expression levels were detected in all HCC samples. The expression was positively correlated with the upregulation of Interleukin-10 (IL-10) in tumor cells, 33 an immunoregulatory cytokine known to downregulate the immune response in cancer. In parallel with this study, Wang et al. 34 reported B7-H1 expression in 24 of 26 (93%) frozen HCC tissue samples. The B7-H1 expression was significantly associated with the earlier tumor stage. However, no significant correlation was found between B7-H1 expression and the tumor grade. 34 Recently, Chen et al. 31 demonstrated high grade B7-H1 expression in 29 of 63 (46%) HCC cases. The expression was detected in both the membrane and cytoplasm of the tumor cells. High B7-H1 expression was significantly associated with the infiltration of tumor-associated macrophages, 31 a cell population known to downregulate the immune response in cancer.
Intrahepatic Cholangiocarcinoma (ICC)
Intrahepatic cholangiocarcinoma (ICC) is a primary malignancy of liver that arises from the bile duct epithelium. It is the second most common cancer of the liver after HCC. 36 Ye et al. 36 reported B7-H1 expression in paraffin-embedded specimens from 31 of 31 (100%) ICC patients. B7-H1 expression was significantly higher in ICC cells than in the adjacent tissue. Elevated B7-H1 expression was associated with poor histological differentiation and advanced tumor-nodal-metastatic (TNM) stage. The density of CD8+ TILs (a cytotoxic T cell population known to eliminate cancer cells) was inversely correlated with intratumoral B7-H1 expression. Apoptotic CD4+ and CD8+ TILs count was higher in the cases with elevated B7-H1 expression compared with the cases of lower expression. The difference, however, did not reach statistical significance. 36 
Colon cancer
Overexpression of B7-H1 molecule has been implicated in the immune escape of several human malignancies, including colorectal carcinoma.
9,37,38 Dong et al. 9 were the first to detect the B7-H1 presence via immunohistochemical analysis in 10 of 19 (53%) frozen samples of colon cancer patients.
In 2005, Xiao et al. 38 detected B7-H1 molecule in TILs via in situ hybridization on paraffin-embedded colorectal carcinoma samples. Significantly more elevated expression levels of this molecule were observed in the tumor cells than in TILs. Metastasis of colorectal carcinoma was correlated with an increase in the expression level of B7-H1 in both tumor cells and TILs. Moreover, the expression in TILs was significantly associated with the degree and depth of tumor invasion. The study concluded that B7-H1 overexpression could be involved in the apoptosis of TILs in colorectal carcinoma patients and thus promote immune escape of tumor cells. 38 Hua et al. 37 reported high B7-H1 expression in 15 of 33 (45%) cases of colorectal carcinoma. There was a significant inverse correlation between B7-H1 expression and CD3+ TILs density in the tumor nest and the tumor stroma. The densities of CD4+/ Foxp3+ and CD8+/Foxp3+ Tregs in B7-H1 high group were significantly higher than those of the B7-H1 low group. Other clinicopathological factors were not determined. 37 
Pancreatic cancer
The B7-H1 expression was demonstrated in pancreatic cancer patients for the first time by Nomi et al. in 2007 . 43 The expression was detected in 20 of 51 (39%) frozen tumor samples. The B7-H1 status was determined to be a significant independent prognostic factor. B7-H1 positive patients had significantly worse survival rates compared with B7-H1 negative patients. B7-H1 expression had a significant inverse correlation with CD4+ TILs and CD8+ TILs. However, no significant correlation was found between B7-H1 and tumor, nodal, metastatic statuses, and pathologic stage. 43 Geng et al. 40 reported B7-H1 expression in paraffin-embedded tumor samples of 40 pancreatic cancer patients. The expression was predominantly observed in the cytoplasm of tumor cells. B7-H1 expression was significantly higher in pancreatic carcinoma tissues than in the normal tissue. Positive B7-H1 status was significantly associated with advanced tumor stage and poor tumor differentiation. However, the expression did not correlate with the size of the tumor. A positive correlation was demonstrated between intratumoral B7-H1 overexpression and IL-10 level at both the mRNA and protein levels. 40 Loos et al. 42 also demonstrated B7-H1 expression in paraffin-embedded tumor samples. B7-H1 expression was detected in pancreatic cancer cells, tumorsurrounding tubular complexes, pancreatic islet cells, TILs, and endothelial cells. The expression in pancreatic cancer cells was significantly correlated with postoperative survival. B7-H1 positive status was also associated with the increased prevalence of Foxp3+ TILs Tregs compared to B7-H1 negative tumors. However, it did not reach statistical significance (P = 0.06). 42 Later in 2009, Huang et al. 41 also reported elevated expression levels of B7-H1 in tissues of 60.5% patients with pancreatic carcinoma. No significant expression was observed in normal samples. B7-H1 positive status was significantly associated with IL-10 level in tumor tissues. Similarly, Chen et al. 39 determined B7-H1 expression in 18 of 40 (45%) pancreatic cancer patients. B7-H1 expression was significantly correlated with advanced tumor stage, and was demonstrated to be an independent poor prognostic factor. 39 A year later, Wang et al. 44 reported significantly higher B7-H1 expression in pancreatic carcinoma tissues than in normal samples. B7-H1 expression was significantly correlated with tumor pathological grade, and it was a prognostic indicator of poor disease-specific survival. All of these studies indicate a possible role of B7-H1 in immune escape of pancreatic cancer cells. 44 Ovarian cancer B7-H1 has been implicated in the immune evasion of various tumors, including ovarian cancer. [8] [9] [10] [11] In 2007, Hamanishi et al. 11 investigated the expression of B7-H1 in paraffin-embedded specimens of 70 ovarian cancer patients. Their study revealed that elevated B7-H1 expression levels were associated with poor prognosis. The overall survival rate of five years in high B7-H1 expression patients was significantly worse than in those who had a lower B7-H1 expression. Moreover, the progression-free survival rate of high expression patients was significantly lower compared to patients with lower expressions of this molecule. Multivariate analysis concluded that B7-H1 was an independent poor prognostic factor for both progression-free and overall survival of ovarian cancer patients.
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Breast cancer Breast cancer is the leading cause of cancer related deaths in women. 74, 75 The first study demonstrating the presence of B7-H1 molecule expression in breast cancer patients was documented by Ghebeh et al. (2006) . 4 The correlation of this molecule with the clinicopathological status of the malignancy was investigated in frozen tumor samples of 44 breast cancer patients. 4 B7-H1 expression (membranous and/or cytoplasmic) was detected in the tumor cells and/or TILs of 50% of breast cancer patients. The expression was totally absent in healthy tissue areas of the affected breast. B7-H1 expression was found to be significantly correlated with bad prognostic factors including large tumor size, histology grade III tumors, negative estrogen receptors, negative progesterone receptors, and human epidermal growth factor receptor 2 (Her2/neu) negative status. 4 A year later, these findings were further confirmed by the same group in their follow-up study of 69 breast cancer patients.
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B7-H1 expression was also demonstrated to be associated with the proliferative potential of the tumor cells. 5 The B7-H1 expression was significantly correlated with the Ki-67 proliferative marker and a high mitotic index. Most tumor cells simultaneously revealed expression of B7-H1 and nuclear expression of Ki-67. 5 Moreover, the association of B7-H1 positive TILs with Foxp3+ Tregs in the tumor microenvironment was investigated by Ghebeh et al. (2008) . 6 B7-H1 expression in TILs within the tumor environment was significantly correlated with the presence of Foxp3+ Tregs 6 In their subsequent investigation in 2010, Ghebeh et al., 7 demonstrated that doxorubicin was able to downregulate the B7-H1 cell surface expression and to upregulate its nuclear expression in breast cancer cells. Blockade of B7-H1 via small interfering ribonucleic acid (siRNA) led to significantly enhanced apoptosis in 90% of the breast cancer cells. Furthermore, Akt pathway inhibition and doxorubicin treatment synergistically lowered both the cell surface and nuclear expression of B7-H1 molecule in the tumor cells. 7 These studies therefore suggest that immunotherapeutic targeting of PD-L1/PD-1 pathway in breast cancer patients in conjunction with the available therapeutic modalities can facilitate the effectiveness of other anti-tumor treatment strategies. 76 
Cervical carcinoma
Cervical cancer is the second most common malignancy reported in women (after breast cancer) around the globe. [77] [78] [79] [80] [81] In 2009, Karim et al. 12 reported intratumoral B7-H1 cell surface expression in paraffinembedded sections of 22 of 115 (19%) cervical cancer patients. The expression was significantly associated with increased intraepithelial infiltration by Foxp3+ T cells (P = 0.022). However, it did not correlate with the survival of the patients. 12 This lower percentage of B7-H1 positive cervical cancer patients and its negative correlation with survival can be attributed to the fact that 51 patients in the study had already received post-operative radiotherapy. Further studies on frozen specimens and untreated patients are required to investigate the correlation of B7-H1 expression with the prognostic factors of the disease.
Squamous cell carcinomas of the head and neck (SCCHN)
Head and neck carcinomas account for 5% of all cancers, and over 90% of them are squamous cell carcinomas. 82 In 2003, Strome et al. 17 demonstrated B7-H1 expression in 16/24 (66%) frozen tumor samples of squamous cell carcinomas of the head and neck (SCCHN) patients. Both intracytoplasmic and membrane expressions were observed. Clinical and prognostic correlations were not determined in this study. 17 Later in 2013, Lyford-Pike et al. 16 reported B7-H1 expression in 14/20 (70%) paraffin-embedded specimens of human papilloma virus-associated head and neck squamous cell carcinomas (HPV-SCCHN). Cell surface expression was observed in cancer cells at the tumor periphery and CD68+ tumor-associated macrophages. However, the clinical and prognostic correlations were not determined.
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B7-H1 expression in oral squamous cell carcinomas (OSCC) was studied by Malaspina et al. 14 and Cho et al. 13 In 2011, Malaspina et al. 14 reported expression in 38/39 (97%) frozen tumor samples of OSCC patients. B7-H1 expression was highly expressed in CD14+ TILs.
14 In a similar study, Cho et al. 13 demonstrated expression in 39 of 45 (87%) paraffin-embedded specimens of OSCC subjects. The expression was both membranous and cytoplasmic in the tumor cells. Tumor-associated fibroblasts were also found to be positive for B7-H1 expression in 18 of 45 (40%) patients. Its expression by the tumor cells did not affect the survival of OSCC patients. However, it was significantly correlated with less differentiated OSCC cells. A decrease in the number of TILs in the tumor environment was also correlated with the expression of B7-H1. However, the B7-H1+ tumor-associated fibroblasts had no impact on the clinical parameters of the patients. 13 Nasopharyngeal carcinoma (NPC) NPC is the third most common malignancy of East Asia with the incidence of 15-50 cases per 100, 000 population.
83 B7-H1 expression has been investigated in nasopharyngeal carcinomas (NPCs). 26, 27 In 2008, Zhang et al. 27 reported expression in 40 of 59 (68%) NPC patients. The expression was significantly correlated with advanced tumor stage and lymphatic metastasis. 27 Later, Hsu et al. 26 demonstrated expression in paraffin-embedded tumor samples of NPC patients. However, the expression was not associated with the clinical outcomes of the patients. This might be due to the fact that all 28 patients involved in the study had already completed curative chemo/ radiotherapy. 26 Further studies of untreated patients are required to confirm the clinicopathological significance of B7-H1 in NPCs.
Esophageal cancer
Esophageal cancers are the seventh leading cause of cancer related mortalities in the US, with a five-year survival rate of merely 17%. 84 In 2005, Ohigashi et al. 29 reported B7-H1 expression in 18 of 41 (44%) frozen specimens of squamous esophageal cancer patients. The expression was observed both in the membrane and the cytoplasm of the tumor cells. The overall survival of B7-H1 positive patients was significantly worse than that of B7-H1 negative patients. B7-H1 status was a highly significant independent prognostic factor.
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B7-H1 expression has also been reported in Barrett's carcinoma (adenocarcinoma of the distal esophagus). 28 Barrett's carcinoma is one of the most aggressive malignancies and arises from intestinal metaplasia. 28 In 2011, Loos et al. 28 demonstrated B7-H1 expression in paraffin-embedded specimens of 74 of 101 (73%) Barrett's carcinoma patients. It was abundantly expressed in the tumor and the TILs cell membrane and cytoplasm. Elevated intratumoral B7-H1 expression was significantly associated with advanced tumor size and invasiveness, as well as increased risk of mortality from cancer. A high expression of B7-H1 was also associated with a twofold lower median prevalence of TILs (0.32 versus 0.67). However, the correlation was not statistically significant (P = 0.06). 28 Urothelial cancer Urothelial cancer is the second most common malignancy of the genitourinary tract. 85 The disease is the second most common cause of deaths related to genitourinary tumors. 85 In 2007, Inman et al. 52 reported B7-H1 expression in paraffin-embedded specimens of 79 of 280 (28%) urothelial cancer patients. The expression was detected in the plasma membrane of the tumor cells. B7-H1 was significantly associated with advanced grade tumors. The expression of B7-H1 was also a significant determinant of the status of tumor stage progression.
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In the same year, Nakanishi et al. 53 demonstrated B7-H1 expression in the frozen tumor samples of patients with urothelial cancer. Focal pattern expression was detected in the membrane and the cytoplasm of cancer cells. B7-H1 was significantly correlated with the tumor grade, and was notably associated with primary tumor classification. Elevated B7-H1 expression was significantly associated with poor survival compared with low grade B7-H1 expression. Postoperative tumor recurrence was also significantly associated with higher B7-H1 expression. 53 In 2008, Boorjian et al. 51 detected B7-H1 expression in 39 of 314 (12%) paraffin-embedded tumor samples. Predominant membrane and occasional cytoplasmic expression were observed in the tumor cells. The expression was significantly related to advanced disease stage at cystectomy. Considerably elevated B7-H1 expression was observed in tumors with greater number of PD-1 positive TILs. The expression was a significant predictor of mortality after cystectomy. Subjects with organ confined B7-H1 positive tumors were three times more likely to die after cystectomy than B7-H1 negative patients. 51 Later, Wang et al. 86 reported B7-H1 expression in 36 of 50 (72%) paraffin-embedded tumor samples. B7-H1 expression was significantly associated with the tumor grade and the clinical stage of the disease. B7-H1 positive patients had significantly poorer survival than B7-H1 negative subjects. Furthermore, the expression of B7-H1 molecule was demonstrated to be an independent prognostic factor of urothelial cancer of the bladder. 86 Renal cell carcinoma (RCC) Renal cell carcinoma (RCC) is the thirteenth most common cancer worldwide. 87 The disease is usually asymptomatic during early stage but is highly metastatic. In 2004, Thompson et al. 47 reported B7-H1 expression in 130 of 196 (66%) frozen RCC samples. Expression was detected both in tumor cells and TILs. High intratumoral B7-H1 expression was significantly associated with adverse pathological features that included higher nuclear grade, regional lymph node involvement, histological tumor necrosis, and distant metastasis. Patients with elevated B7-H1 expression levels (either in TILs or tumors) were 4.5 times more likely to die from RCC than patients who had lower B7-H1 expression. 47 In 2005, the same group investigated B7-H1 expression in 17 of 26 (65%) frozen metastatic RCC tumor samples. 48 Expression was detected in tumor cells and TILs. High B7-H1 expression (in tumors and/or TILs) was significantly associated with increased risk of death. B7-H1 positive patients were four times more likely to die from RCC than B7-H1 negative patients. The expression was significantly associated with metastatic progression. 49 The following year, Krambeck et al. 46 reported on the expression of B7-H1 in 70 of 298 (24%) paraffinembedded specimens of RCC. B7-H1 positive patients were four times more likely to die from RCC than B7-H1 negative patients. The expression was independently associated with death from RCC. 46 Wilms' tumor (nephroblastoma) Wilms' tumor or nephroblastoma is the second most common renal malignancy of childhood. 88 In 2008, Routh et al. 89 demonstrated B7-H1 expression in 11 of 81 (14%) paraffin-embedded Wilms' tumor specimens. Intratumoral B7-H1 expression was associated with a threefold increased risk of recurrence. However, this association did not reach statistical significance (P = 0.057). Nonetheless, patients with B7-H1 positive favorable tumor histology were at significantly increased risk of disease recurrence (P = 0.027) than subjects with B7-H1 negative favorable tumor histology. 89 
Melanoma
Melanoma is the deadliest malignancy among skin cancers. It is responsible for 50,000 deaths each year worldwide, and its incidence is still rising. 90 Advanced stage patients have a median survival of one year only. The available treatments prolong the lives of patients but do not completely cure the disease. 90, 91 In 2010, Hino et al. 55 reported high B7-H1 expression in 34 of 59 (58%) paraffin embedded melanoma specimens. Tumor thickness was significantly higher in the high expression group than in the lower expression group. Advanced tumor stage had significantly more elevated B7-H1 expression than in those with less advanced tumors. Patients with lymph node metastasis had a significantly higher B7-H1 expression than patients without lymph node metastasis. Patients with high B7-H1 expression also had significantly lower overall survival than the lower expression patient group, thus indicating that B7-H1 expression was an independent predictor of overall survival. 55 Similarly, Gadiot et al. 54 reported B7-H1 expression in paraffin-embedded specimens of 63 melanoma patients. Higher frequency of B7-H1 positive staining was detected in satellite metastases (25%), and in intransit metastases (40%). B7-H1 expression was shown to increase with disease progression. 54 Recently, Taube et al. 56 demonstrated B7-H1 expression in 57 of 150 (38%) paraffin-embedded melanoma patients. The study found 98% of B7-H1 positive samples were highly associated with TILs compared to 28% of the B7-H1 negative cases. B7-H1 expression was significantly associated with inflammatory infiltrates. Clinicopathological factors, including tumor thickness and TNM stage, were not associated with B7-H1 expression. Further, B7-H1 expression in metastatic melanoma patients correlated with significantly improved survival. This result can, however, be misleading because 43% of the metastatic melanoma patients involved in the study had already received systemic immunotherapy, including high dose interleukin-2 (IL-2), IFN-a, anti-PD-1 monoclonal antibody/vaccine, or combinations of these agents. 56 Further studies (preferably on frozen samples) of untreated patients are required to investigate the possible role of B7-H1 in the immune escape of melanoma cells and in the overall survival of melanoma patients.
Brain tumors
Brain tumors account for 2% of all the malignancies. 19 The most common brain tumors are meningiomas and gliomas. 19 In 2003, Wintterle et al. 21 reported B7-H1 expression in glioma patients. The expression was detected in 10 of 10 (100%) frozen tumor samples of glioma patients. More than 50% of the cells in 50-90% of the tumor samples expressed B7-H1. 21 Two years later, Wilmotte et al. 20 demonstrated B7-H1 expression in 46 of 54 (85%) frozen glioma samples. Significantly intense B7-H1 staining, with more than 30% positively stained cells, was detected in 18 of 33 samples of high grade anaplastic astrocytoma and glioblastoma compared with diffuse astrocytoma and oligodendroglioma samples. B7-H1 expression was therefore correlated with tumor grade. 20 In 2009, Yao et al. 22 detected B7-H1 expression in 36 of 48 (75%) frozen glioma samples. The expression was significantly higher in advanced grade gliomas than in low grade tumors. Intratumoral B7-H1 expression was negatively correlated with the number of cytotoxic CD8+ T cells. 22 Similarly, Jacobs et al. 19 reported B7-H1 expression in 51of 83 (61%) paraffinembedded brain tumor samples (meningiomas, gliomas, adenomas and schwanomas). Later, Avril et al. 18 demonstrated B7-H1 expression in 10 of 20 (50%) paraffin-embedded tumor samples. However, the clinicopathological correlations of B7-H1 were not determined in these studies. 18 Thymic neoplasms (thymomas) Thymomas are tumors that originate from the thymus, and have a worse prognosis at advanced stages.
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B7-H1 expression in thymomas was detected by Brown et al. (2003) . 8 Ten out of 15 (67%) samples of benign thymoma, 11 of 11 (100%) samples of invasive thymoma, and 7 of 8 (88%) samples of thymic carcinomas were B7-H1 positive. Overall, 82% of the total 34 samples showed B7-H1 expression. Clinicopathological correlations were not determined.
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B7-H1 expression in hematological malignancies Lymphomas Lymphomas are the malignancies of B/T lymphocytes. Lymphomas account for 55.6% of all blood cancers.
93 B7-H1 expression has been reported in the following lymphomas:
Peripheral T cell lymphoma (PTCL). Peripheral T cell lymphoma (PTCL) is the most common form of T cell lymphoma, and is aggressive. It is a sub-type of non-Hodgkin's lymphoma (NHL). 94 In 2003, Brown et al. 8 detected B7-H1 via immunohistochemical analysis of 7 of 11 (64%) samples of PTCL. In 2009, Wilcox et al. 59 reported B7-H1 expression in 22 of 144 (15%) PTCL samples using immunohistochemical analysis. The expression was detected in tumor cells and monocytes. However, the clinicopathological associations of B7-H1 were not determined in these studies.
Cutaneous T cell lymphoma (CTCL). Cutaneous T cell lymphoma (CTCL) is a subtype of NHL that presents in the skin. 95 In 2009, Wilcox et al. 59 demonstrated B7-H1 expression in 3 of 11 (27%) paraffinembedded specimens of CTCL. The expression was detected in tumor cells and monocytes. The clinicopathological associations of B7-H1 were not determined. 59 Adult T-cell lymphoma (ATL). Adult T-cell lymphoma (ATL) is a rare but highly aggressive subtype of NHL. 96 In 2009, Kozako et al. 58 demonstrated increased B7-H1 expression in 5 of 23 (22%) cases of ATL patients. B7-H1 expression was detected in CD4+/CD25+ T cells. No expression was observed in de novo ATL patients. However, more than 10% CD4+/CD25+ T cells of the 22% ATL patients showed the expression one year after diagnosis. No clinicopathological correlations of B7-H1 were investigated. 58 Diffuse large B cell lymphomas (DLBLC). Diffuse large B cell lymphomas (DLBLC) is the most common type of NHL among adults, 97 and is aggressive. It has an annual incidence of seven to eight cases per year. 97 In 2011, Andorsky et al. 98 reported B7-H1 expression in 9 of 33 (27%) frozen samples via immunohistochemical analysis. Clinicopathological significance of B7-H1 was not determined in this study. 98 
Leukemia
Leukemia is the eleventh most common cause of cancer-related deaths worldwide. 99 The expression of the B7-H1 molecule and its clinicopathological correlations have been studied in both acute and chronic leukemias. [60] [61] [62] [63] [64] [65] [66] [67] [68] In 2006, Salih et al. 60 reported B7-H1 expression in a cohort of patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) and chronic lymphoblastic leukemia (CLL). Overall, 17 of 30 (57%) cases were B7-H1 positive. 60 A year later, Li et al. 61 investigated B7-H1 expression in 59 AML/ALL patients. The expression was significantly high in relapsed patients, and newly diagnosed patients had lower levels of B7-H1 expression than normal controls. Furthermore, the expression was significantly higher in non-complete remission patients after therapy than in patients with complete remission. B7-H1 was correlated with response to therapy. 61 The following year, Chen et al. 62 reported B7-H1 expression in 25 of 60 (42%) AML/ALL patients. Significantly higher expression was detected in relapsed AML patients than in the newly diagnosed subjects. B7-H1 positive AML subjects had significantly reduced survival compared to B7-H1 negative subjects. B7-H1 proved to be an independent prognostic factor. Immunotherapeutic efficacy was significantly reduced in B7-H1 positive patients than in B7-H1 negative subjects. Moreover, B7-H1 was significantly upregulated in patients following immunotherapy. 62 In 2009, Ge et al. 64 detected B7-H1 expression in 42 of 42 (100%) AML patients. More than 5% of AML cells were B7-H1 positive in 18 of 42 (43%) of leukemia samples. The expression was significantly higher in the leukemic cells of AML patients than in the bone marrow mononuclear cells of healthy volunteers. 64 In 2010, Berthon et al. 65 reported high B7-H1 expression in 14 of 79 (18%) of AML patients. Spontaneous expression was significantly increased in 5 of 9 (56%) of relapsed patients. 65 In 2012, Sun et al. 67 studied B7-H1 expression in 50 AML patients. The expression was lower in de novo AML patients than in the healthy volunteers. However, it was highest in the relapsed patients. B7-H1 expression before therapy was significantly higher in non-cytogenetic remission patients than in patients in complete remission. B7-H1 gene expression was therefore correlated with response to therapy. 67 In the same year, Li et al. 63 studied B7-H1 expression in 74 AML/ALL patients. The expression was significantly higher in non-complete remission patients after therapy compared with patients in complete remission. B7-H1 gene expression was correlated with response to therapy. 63 Grzywnowicz et al. 68 demonstrated B7-H1 expression in 44 of 44 (100%) of CLL patients. B7-H1 expression was significantly higher in CLL patients than in the peripheral blood/bone marrow mononuclear cells of healthy volunteers. The expression was significantly higher in tyrosine kinase zeta-associated protein (ZAP-70) positive subjects compared with ZAP-70 negative patients. 68 These studies suggest a possible role of B7-H1 in the immune escape of leukemic cells and its association with response to therapy.
Multiple myeloma (MM)
Multiple myeloma (MM) is the second most common hematological malignancy in the western world after NHL, and accounts for 10% of all blood cancers. 100 In 2007, Liu et al. 72 detected B7-H1 expression in a majority of 82 MM patients. The expression was significantly higher in plasma cells in MM patients than in non-MM subjects. Very recently, Tamura et al. 70 reported B7-H1 expression in 10 of 40 (25%) MM cases. The expression was significantly associated with increased serum lactate dehydrogenase levels and the percentage of myeloma cells in the bone marrow. Furthermore, the expression of B7-H1 tended to be higher in advanced stage patients. However, its association did not reach statistical significance. B7-H1 expression was upregulated in patients who relapsed or became resistant to anti-MM therapy. 70 
MECHANISM OF B7-H1 MEDIATED TUMOR CELL IMMUNE RESISTANCE
B7-H1 is a member of the B7 family of immunoregulatory molecules. 4, 101 It is a surface glycoprotein known to be expressed on conventional CD4+ and CD8+ T cells, dendritic cells (DCs), macrophages, B cells, Tregs, epithelial cells, endothelial cells, immune privileged sites such maternal-fetal barrier, 4, 101 and on a majority of tumor cells (Table S1 ). Both co-stimulatory and co-inhibitory characteristics of B7-H1 molecule have been reported. [102] [103] [104] The inhibitory behavior of B7-H1 molecule is attributed to its binding with a co-inhibitory receptor, PD-1, also known as CD 279.
9,105 PD-1 is expressed on Tregs, B cells, antigen-activated CD4+ and CD8+ T cells, natural killer (NK) cells, and frequently on TILs. 106 In contrast, the stimulatory role of B7-H1 has been ascribed to its binding with yet unidentified, co-stimulatory non-PD-1 receptors. 9, 103 Classical mechanism of adaptive immune response activation Dendritic cells (DCs) are the most pivotal of antigen presenting cells (APCs) that initiate immune responses. 107 Immature DCs express major histocompatibility complex class-II (MHC-II) and other costimulatory molecules, and reside in non-lymphoid tissues. 108 DCs upregulate MHC-II molecules on their cell surfaces and migrate to the lymphoid tissues upon stimulation with foreign invaders or other danger-associated molecules. At this stage, they may encounter naïve T cells. 108 Activation of naïve CD4+ T helper cells requires the linkage of the T cell receptor (TCR) with antigen loaded MHC-class II complex on mature DCs, while the activation of CD8+ cytotoxic T lymphocytes (CTLs) requires the binding of the TCR with antigen-loaded major histocompatibility complex class-I (MHC-class I) complex on APCs. 109 This is known as Signal 1.
109
Following Signal 1, another co-stimulatory signal is required for the T cells to induce an effective immune response and thereafter the induction of apoptosis in the target cell. 110 CD28 is the principal co-stimulatory receptor expressed on both CD4+ T helper and CD8+ CTLs. 110, 111 Successful simultaneous generation of Signal 1 and binding of CD28 to their costimulatory ligands, B7-1 (also known as CD80) or B7-2 (also known as CD86), on DCs/APCs generates Signal 2. 112 This second signal stimulates T cells by reducing the threshold of TCR signaling, which is accomplished by the formation of immunological synapse, triggering IL-2 production and upregulation of Bcl-X2 anti-apoptotic protein which protects T cells from apoptosis. 113, 114 Subsequent proliferation of T cells and their secretion of cytokines and cytolytic molecules, such as perforin and granzyme, cause tumor/target cell death 112 (Fig. 1A) .
B7-H1 upregulation and dampening of immune responses
Absence of Signal 2 renders T cells anergic. 114 Persistent antigen presentation leads to upregulation of PD-1 on T cells, which is followed by the expression of B7-H1 on APCs in the local tissue.
115 Subsequent B7-H1/PD-1 interaction inhibits TCR signaling by recruiting the Src homology region 2 domain containing phosphatases 1 and 2 (SHP-1, SHP-2). 116 These enzymes mediate a stop signal, and thus limit the interaction of APCs/DCs with T cells. 117 This overexpression and interaction of inhibitory molecules causes exhaustion and/or apoptosis of T cells by impairing their metabolism, inhibiting the release of Bcl-X2 anti-apoptotic protein, 113, 114 impairing effector cytokine production (such as IL-2 and IFN-c) and T cell proliferation. 115, 118, 119 The B7-H1/PD-1 axis has also been demonstrated to increase the number of Foxp3+ Tregs in the local tissue environment, 120 which further inhibits the immune response by contributing to the suppression of production of effector cytokines and proliferation of effector T cells. 121, 122 It has been demonstrated that B7À/À mice are deprived of the ability to produce Tregs. 6, 123 Blockade of B7-H1 has been shown to prevent Treg-mediated immune regulation, 124 indicating the crucial role of B7-H1 in the generation and immunoregulatory function of Tregs. Moreover, Amarnath et al. 125 have shown that B7-H1/PD-1 interaction is also responsible for converting human T helper 1 (Th1) cells to Tregs in vivo, and prevents the onset of human to mouse xenogeneic graft versus host disease (xGVHD). Blockade of the B7-H1/PD-1 pathway or inhibition of SHP-1/SHP-2 was shown to restore Th1 differentiation and to induce xGVHD. 125 It has been observed that tumor sites are often loaded with TILs. 126 Logically, this should aid the immune system in the clearance of tumor cells. Indeed, in ovarian 127 and gastric cancer 128 patients, the infiltration of T cells, myeloid DCs, and NKs has been associated with a better prognosis. However, this factor has also been associated with a poor prognosis in B7-H1 MOLECULE ROLE IN CANCER review B7-H1 positive RCC patients. 129 Furthermore, the B7-H1 positive status is linked to tumor metastasis and increased risk of mortality in RCC subjects. 49, 129 B7-H1 expression could thus be responsible for the association of TILs with poor prognosis as tumor cells might exploit the B7-H1 expression to overcome anti-tumor immune responses mediated by TILs. 126 Mechanisms of B7-H1 upregulation by tumor cells The expression of B7-H1 by tumor cells depends on two kinds of mechanisms: innate and adaptive immune resistance. 130 Innate resistance corresponds to B7-H1 upregulation by oncogenic signaling pathways in the tumor cells. 130 For example, phosphatase and tensin homolog (PTEN) loss in breast cancer cells 131 and gliomas 132 activates phosphatidylinositide 3-kinase/ Akt (PI3K/Akt) and phosphatidylinositide 3-kinase/ mammalian target of rapamycin (PI3K/mTOR) pathways which subsequently result in B7-H1 overexpression. Likewise, anaplastic lymphokinase signaling in lymphomas and lung cancer upregulates B7-H1 via signal transducer and activator of transcription 3 (STAT 3) signaling. 133 Toll-like receptor 4 has also been reported to upregulate B7-H1 expression on macrophages by lysophosphatidylserine-dependent signal transducer and activator of transcription 1 (STAT 1) signaling mechanism 134, 135 (Fig. 1B) . Adaptive immune resistance refers to the exploitation of PD-1 ligand; B7-H1 by tumor cells to evade endogenous immune response.
130 B7-H1 is normally expressed to protect a tissue from immune attack. However, cancer cells exploit it to protect themselves from cytolysis. 130 The adaptive immune resistance of tumor cells can be ascribed to the observation that B7-H1 expression is often induced by interferons, mainly IFN-c. [136] [137] [138] Although IFN-c is known for its role in the defense against viral infections, it has been shown to upregulate B7-H1 expression in non-lymphoid tissues. 139, 140 IFN-c plays an immunosuppressive role by inducing the expression of the transcription factor, interferon regulatory factor 1 (IRF-1). IRF-1 then binds to the promoter region of B7-H1 gene and leads to its expression 141 ( Fig. 1B) . B7-H1 upregulation has been observed at inflammatory sites in the encephalomyelitis model, 142 and in muscle biopsies from inflammatory myopathy patients. 143 Recently, Taube et al. 56 have reported a significant correlation of B7-H1 expression in melanoma cells with IFN-c expression in the tumor microenvironment. Thus, the benefit of IFN-c in the autoimmune setting, and its role in tumor immune tolerance might be attributed in part to the upregulation of B7-H1 at inflammatory sites, which subverts immune responses by B7-H1/PD-1 interaction.
TARGETING THE B7-H1 MOLECULE
B7-H1 blockade by anti-B7-H1 monoclonal antibody and soluble recombinant peptide Antibodies that target tumor cell-associated B7-H1 block its engagement with the PD-1 receptor on T cells. This allows CTLs to launch an effective immune response against the B7-H1 positive tumor cells. 130, 144 Moreover, anti-B7-H1 monoclonal antibodies (mAbs) could likely lead to tumor cell death by the NK cell mediated-antibody dependent cell cytotoxicity (ADCC) pathway. 145 In this pathway, the Fc receptor of NK cells binds with the Fc domain of the tumor cell bound anti-B7-H1 mAb, resulting in tumor cell lysis through the production of effector cytokines (such as IFN-c, IL-2) and cytotoxic granules 145 ( Table 1) . Very recently, Brahmer et al. 146 examined the safety and efficacy of BMS-936559, a human B7-H1 specific IgG4 mAb in a Phase I clinical trial. The study involved 207 patients with cancers that included melanoma, RCC, NSCLC, ovarian, pancreatic, gastric and breast cancers in advanced stages. Objective responses were reported in 2 of 17 RCC, 5 of 49 NSCLC, 9 of 52 melanoma, and 1 of 17 ovarian cancer patients. No response was observed in any of the patients with B7-H1 negative tumors; however, 6-17% of the patients showed durable tumor regressions. Prolonged disease stabilization was observed in 12-41% of the patients with advanced melanoma, and with RCC and NSCLC patients at six months' follow-up. Importantly, none of the patients developed pneumonitis and the rate of treatment-related grade 3-4 adverse events were 9%. 146 Conversely, 3% cases of pneumonitis and 14% grade 3-4 adverse events were reported on an anti-PD1 clinical trial by Topalian et al. 147 This could be partly explained by the fact that B7-H1 blockade spares B7-DC, a molecule which is expressed only in a minority of human cancers.
145 B7-DC blockade in mice has been reported to excessively increase T helper cell 2 (Th2) immune response, exacerbating inflammation of respiratory tract. 148 Hyperactivation of Th2 cells is also associated with increased production of interleukin 4 (IL-4) which is known to dampen Th1 immune response. 145, 148, 149 B7-DC sparing could thus prevent the onset of severe toxic inflammation, lower the occurrence of anti-B7-H1 mAb-related adverse events, and prevent a decline in Th1 activity against the tumor cells.
A recombinant peptide, soluble programmed death 1 in conjunction with CH50 fibronectin domain (sPD-1-CH50) is known to bind to B7-H1 and inhibit its interaction with the PD-1 in a murine hepatoma model. 150 This strategy has been shown to enhance the recruitment and cytotoxic activity of T cells/macrophages against B7-H1 positive tumor cells and to increase the production of effector T cell cytokines ( Table 1 ). The sPD-1-CH50 treatment was also shown to inhibit the growth and metastasis of the tumor cells in vivo. 150 Blockade of B7-H1 by anti-B7-H1 mAbs and sPD-1-CH50 therefore has a potential therapeutic significance for the inhibition of growth and invasion of tumors, as well as the acceleration of anti-tumor immunity.
B7-H1 suppression by chemotherapeutic drugs
Chemotherapeutic drugs are designed to treat cancers by inducing apoptosis and inhibiting proliferation of tumor cells. 151 They include anthracyclines (e.g. doxorubicin, danorubicin), alkaloids (e.g. doxetaxcel, sinonemine), alkylating agents (e.g. cisplatin), and pyrimidine antagonist (e.g. arabinofuranosyl cytidine; Ara-C). However, these drugs may also have immunomodulatory properties. 7, 152, 153 Doxorubicin, an anthracycline-based drug used in the treatment of breast cancer, 154 and childhood soft tissue sarcomas and lymphomas, 155, 156 is reported to stimulate the production of cytokines, 157 CTL 158 and NK cell immune responses, 157 enhance differentiation of macrophages, 159 and downregulate cell surface B7-H1 expression in breast cancer cells. 7 Nevertheless, doxorubicin upregulates B7-H1 nuclear expression via Akt dependent pathway in tumor cells which renders them anti-apoptotic. 7 This is because nuclear translocation of B7-H1 molecule can permit its interaction with the apoptotic machinery of the tumor cell. 7 Administration of doxorubicin in conjunction with siRNA-mediated B7-H1 knockdown has been shown to augment doxorubicin-mediated tumor cell apoptosis. 7 A combination of chemotherapy with B7-H1 targeting can therefore be beneficial in overcoming drug-mediated immune resistance of tumor cells and enhancing anti-tumor immunity. Sinomenine, an alkaloid extracted from a Chinese medicinal plant Sinomenium acutum, 160 is well known in the Far East for the treatment of rheumatoid arthritis, [160] [161] [162] autoimmune nephritis, 163, 164 renal allograft rejection, 165 and hepatitis. 165 Sinomenine has been widely recognized for its immunosuppressive and anti-inflammatory properties, 104 and has recently been demonstrated to possess anti-tumoral properties as well. 104 Sinomenine-mediated downregulation of B7-H1 mRNA and protein expression of IFN-c and tumor necrosis factor alpha (TNF-a) treated renal tubular epithelial cells (TECs) has been reported by Chen et al. 104 TECs with B7-H1 overexpression were seen to inhibit cytotoxic cytokine production by T cells in TEC: T cell co-cultures, and sinomenine treatments resulted in significantly enhanced effector cytokine production by the T cells ( Table 1) . The drug could thus be a feasible option for the treatment of RCC. 104 Triptolide, an oxygenated diterpene compound extracted from a Chinese medicinal herb, Tripterygium wilfordii, has been widely used in the Far East for the treatment of autoimmune diseases such as rheumatoid arthritis, and tumors. 166, 167 Triptolide has been shown to induce tumor cell apoptosis both in vitro and in vivo [168] [169] [170] (Table 1) . Moreover, remission rates of 87% in granulocytic leukemia and 71% in mononucleocytic leukemia have been reported in Triptolide clinical trials in China. 171 The anti-tumor property of this compound has been ascribed to its ability to activate caspase-3 and caspase-8, 172 and render tumor cells more susceptible to topoisomerase inhibitors 173 (Table 1) . Triptolide enhances doxorubicin-mediated apoptosis of tumor cells, 168 and downregulates B7-H1 expression in TNF-a regulated TECs by decreasing transcription of nuclear factorkappa light chain enhancer of activated B cells (NFjB).
174 B7-H1 inhibition by triptolide could thus partly explain its anti-tumoral behavior.
Honokiol, a natural dietary product extracted from the seed cones of Magnolia grandiflora, attenuates tumor growth in breast, 175, 176 gastric, 177, 178 colon, 179, 180 pancreatic, 181 and skin cancers. 182 Honokiol inhibits transcription of NF-jB 175 and the (PI3K/mTOR) pathway, 176 both of which are implicated in the upregulation of B7-H1 expression 174 ( Table 1) . Indeed, honokiol has been demonstrated to downregulate B7-H1 expression in PTEN deficient glioma, breast, and prostate cancer cells. 132 Honokiol can therefore be an appealing therapeutic option in overcoming cancer cell immune resistance.
Cyclooxygenase 2 (COX-2) is an enzyme which catalyses the conversion of arachidonic acid to prostaglandins (PG-E2). 183 Over expression of COX-2 has been implicated in inflammation and reported in a number of human cancers including lung, breast, skin, prostate and colon cancers. 183 Nimesulide is a selective COX-2 inhibitor, and is known to inhibit proliferation of tumor cells and induce tumor cell apoptosis in vitro, 184, 185 as well as prevent metastasis in vivo. [186] [187] [188] Nonetheless, it has been suggested that COX-2 independent mechanisms are involved in nimesulidemediated anti-tumor responses. [189] [190] [191] Liang et al. 191 reported the downregulation of B7-H1 expression in IFN-c treated human breast cancer cells. They showed that COX-2 inhibitors other than nimesulide (NS-398 and meloxican) fail to inhibit B7-H1 expression. Furthermore, addition of PG-E2 to IFN-c treated breast cancer cells did not inhibit nimesulidemediated B7-H1 downregulation, which indicated that COX-2/PG-E2 independent mechanisms might be involved 191 ( Table 1) . Inhibition of B7-H1 by nimesulide can therefore be a potential therapeutic strategy to boost anti-tumor immune responses.
Tumor specific B7-H1 gene silencing by siRNA siRNA-mediated gene silencing in conjunction with adoptive T cell therapy using tumor specific T cells provide an opportunity to specifically target tumor cells 192 (Table 1) . Iwamura et al. 192 reported on the generation of CD8+ T cell clones which recognize a tumor antigen specific MAGE-A4-derived peptide. TCR-a and b genes from these CD8+ T cell clones were isolated and transduced retrovirally into human T cells, which expressed B7-H1 upon stimulation with the MAG-A4 positive tumor antigen. In this, the siRNA-mediated knockdown of the B7-H1 molecule is shown to augment the cytotoxic activity of the tumor specific T cells. 192 DC-based vaccines are being explored to boost immunity in patients with chronic viral infections and cancer. However, limited clinical benefits have been observed, suggesting the need to improve the potency of DC-based vaccines. 193 Hobo et al. 194 investigated enhanced cytotoxic cytokine production (IFNc, IL-2, IL-5, TNF-a) by minor histocompatibility antigen (MiHA)-specific CD8+ T cells and memory cells of relapsed leukemia patients upon stimulation with siRNA-mediated B7-H1 knockdown DCs in T cell: DC co-culture experiments. This strategy also augmented the production of granzyme B by antigen experienced CTLs and increased their proliferative capacity. 194 In their recent study, Hobo et al. 193 demonstrated the development of enhanced clinical grade DC vaccine by lipidoid nanoparticle-mediated transfection of DCs with B7-H1 siRNA. The B7-H1 silenced DCs effectively enhanced ex vivo antigenspecific CD8+ T cell responses from transplanted leukemia and lymphoma patients.
193
B7-H1 siRNA treatment of breast cancer cells has also been shown to enhance doxorubicin-mediated apoptosis by knocking down nuclear B7-H1 expression. 7 [See Section 4: Targeting the B7-H1 molecule]. These findings suggest that siRNA-mediated silencing of B7-H1 gene can be utilized to boost anti-tumor immunity in conjunction with tumor-specific adoptive T cell therapy and chemotherapy to augment the efficacy of anti-tumor vaccines.
CONCLUSION
Cancer cells exploit the co-inhibitory B7-H1 molecule to evade the immune system. Overexpression of B7-H1 molecule has been linked to worse prognosis and poor response to anti-cancer therapeutic strategies in several human malignancies. Targeting B7-H1 expression can open the inhibitory gate and render many tumor cell types susceptible to lysis/apoptosis, therefore killing many birds with one stone. This strategy may improve the efficacy of standard available cancer treatments.
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